UMIFENOVIR

Umifenovir is a broad antiviral inhibiting membrane fusion used for influenza and respiratory infections. Side effects include GI upset, headache, allergic reactions, and mild liver enzyme elevations.

Product Description


Mechanism of Action

UMIFENOVIR (ID 32287) exhibits a high-dimensional biochemical activity profile integrating catalytic‑domain modulation, multi‑axis signalling disruption, mitochondrial‑network recalibration, ion‑flux redistribution, redox‑state restructuring, cytoskeletal remodelling, membrane‑electrochemical modulation and transcription‑factor pathway reprogramming. Its molecular architecture supports high‑affinity interaction with catalytic residues, allosteric regulators, hydrophobic receptor pockets, transmembrane helices, nucleotide‑binding pockets, redox‑buffer matrices and polymeric scaffolding complexes—granting broad mechanistic influence across metabolic, genomic, electrophysiological and structural systems.

UMIFENOVIR may reorganise phosphorylation‑flow geometry across ERK/MAPK/JNK/p38 cascades, alter PI3K–AKT survival signalling, shift G‑protein coupling patterns, redistribute Ca²⁺ microdomains, reshape IP₃/DAG signalling topology, and recalibrate cAMP–PKA amplitude dynamics. Mitochondrial impacts include ETC‑complex activation shifts, ATP/ADP turnover modulation, ROS‑threshold displacement, mitochondrial‑membrane potential polarity changes and ER–mitochondrial stress‑signal coupling, making the compound highly valuable for mechanistic and translational research models.

Advanced Research Applications

  • Kinome‑scale catalytic‑cascade mapping and interference modelling
  • Ultra‑resolution ligand docking and conformational‑transition analysis
  • UPR/ER‑stress, mitophagy, autophagy and oxidative‑stress cross‑network characterisation
  • Multi‑omics system reconstruction (RNA‑seq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal mechanics and polymer‑turnover modelling
  • Cell‑fate mapping across apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos
  • Machine‑learning driven SAR/QSAR molecular‑performance prediction

Toxicodynamics & Cellular Hazard Spectrum

  • ROS hyper‑accumulation and antioxidant‑system collapse
  • Mitochondrial fragmentation, ETC shutdown or hyper‑leak states
  • Severe Na⁺/K⁺/Ca²⁺ ionic‑flux dysregulation
  • Cytoskeletal depolymerisation and membrane‑integrity failure
  • NF‑κB, STAT and IRF inflammatory‑axis hyperactivation
  • Engagement of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift including methylation and acetylation imbalance

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C22H25BrN2O3S

Molecular Weight

477.4 g/mol

CAS Number

131707-25-0

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

"Expected to be poorly soluble"

Purity

Purity information is available upon request (COA).

Synonym

umifenovir; 131707-25-0; ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate; 93M09WW4RU; 1H-Indole-3-carboxylic acid, 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-, ethyl ester

IUPAC/Chemical Name

ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate

InChl Key

KCFYEAOKVJSACF-UHFFFAOYSA-N

InChl Code

InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3

References

https://pubchem.ncbi.nlm.nih.gov/compound/131411;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download